Skip to content
Back to meeting Original
Vilma P. Barcia MD, PhD, MSc路 @DrVilmaPBarcia 路 X路路 3 days agoScore70

cabozantinib

Body

馃憦 Huge congratulations to my friend @JHernando3 on presenting the GETNE-T2216/CABOTHYROID trial at #ESMO26!
Promising results with cabozantinib in advanced thyroid cancer: ORR 24%, DCR 89.7% and median PFS 16.1 months.
Great work by @GrupoGetne 馃嚜馃嚫! @Ja_Capdevila @OncoAlert

365 views 路 7 likes 路 7 reposts 路 0 replies

Source: Vilma P. Barcia MD, PhD, MSc 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website鈥檚 feedback page.